By combining state-of-the-art technologies novel and scientific concepts, VectorY’s mission is to bring innovative therapies to patients worldwide.
Location: Netherlands, North Holland, Amsterdam
Employees: 51-200
Total raised: $178.32M
Founded date: 2020
Investors 3
| Date | Name | Website |
| 25.02.2022 | BioGenerat... | biogenerat... |
| - | Forbion | forbion.co... |
| 27.11.2023 | MRL Ventur... | mrlv.com |
Funding Rounds 2
Mentions in press and media 15
| Date | Title | Description |
| 18.09.2025 | Capital meets care: 10 venture capital firms transforming healthcare across Europe | Venture capital remains one of the cornerstones of Europe’s innovation landscape, fuelling the growth of startups across every sector. In our last list, we spotlighted 15 VC firms focused on sustainability, underlining how investors are sha... |
| 16.12.2024 | VectorY Strengthens Leadership Team with appointment of Jim Scibetta as new CEO | • Former CEO, Sander van Deventer to become President of R&D • Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package • Expansion of corpo... |
| 16.05.2024 | enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors | BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder c... |
| 18.01.2024 | VectorY appoints Khurem Farooq to Board of Directors | · CEO and Co-Founder of Aiolos Bio and previous CEO of Gyroscope Khurem Farooq joins as independent board member |
| 29.11.2023 | Check out the Amsterdam startups that raised funding in November; 5 of them are hiring | Read this article in: Amsterdam, renowned for its picturesque canals and historic charm, has increasingly become a hotbed for cutting-edge technology and forward-thinking businesses. The city’s startup scene is characterised by diversity an... |
| 14.11.2023 | Amsterdam’s VectorY Therapeutics closes one of Europe’s largest private biotech financings in 2023 | Read this article in: Amsterdam-based VectorY Therapeutics, a biotech company, announced on Monday that it has secured €129M in a Series A round of funding co-led by EQT Life Sciences and the Forbion Growth Opportunities Fund. Additionally,... |
| 14.11.2023 | VectorY Raises €129M in Series A Financing | VectorY Therapeutics, an Amsterdam, the Netherlands-based biotech company developing vectorized antibody therapies for the treatment of neurodegenerative diseases, raised €129M in Series A funding. The round was led by EQT Life Sciences and... |
| 13.11.2023 | Forbion co-leads €129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 | - |
| 13.11.2023 | Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program | VectorY Therapeutics has secured 129 million euros ($138 million) in a series A financing that will help the Dutch biotech advance its preclinical lead program in amyotrophic lateral sclerosis (ALS). The series A round is one of Europe’s bi... |
| 13.11.2023 | Forbion co-leads €129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 | • Round co-led by Forbion and EQT Life Sciences • Financing will support clinical development of VTx-002, a potentially disease-modifying therapy for Amyotrophic Lateral Sclerosis (ALS) and additional pipeline programs • Successful fundrais... |
Show more